生产企业：Alfasigma, Intercept Pharmaceuticals
INT-787 was initially developed by Intercept Pharmaceuticals and later integrated into Alfasigma's liver disease portfolio following the company's 2023 acquisition of Intercept.
INT-787 was initially developed by Intercept Pharmaceuticals and later integrated into Alfasigma's liver disease portfolio following the company's 2023 acquisition of Intercept.
INT-787 is a next-generation oral farnesoid X receptor (FXR) agonist. Through FXR activation, INT-787 is designed to regulate metabolic, inflammatory, and fibrotic processes, potentially delivering hepatoprotective effects.
INT-787 is currently being assessed in the Phase IIa FRESH trial for severe alcoholic hepatitis.
